Two major Chinese MLCC suppliers, Chaozhou Three-Circle and Jiangsu Boqian New Materials, are pursuing Hong Kong listings to capitalize on surging global demand for MLCCs driven by AI infrastructure growth.
Chinese lithography firm CFMEE plans a Hong Kong IPO next week, aiming to raise up to $410 million to fund strategic investments, R&D, and capacity expansion as China pursues semiconductor self-sufficiency.
Shanghai-based GPU designer MetaX announced plans for a Hong Kong listing, aiming to raise capital for R&D, expansion, and strategic investments. The proposed H-share offering, representing up to 5% of enlarged capital, follows its recent debut on Shanghai's Star Market.
AI developers MiniMax Group and Knowledge Atlas Technology are listing in Hong Kong before pursuing mainland China stock offerings. This strategy aims to establish international valuations and attract global investors.
Eight mainland China-based companies, including five biotech firms, passed listing hearings on the Hong Kong stock market in April. Metis, founded in 2020 in Hangzhou, uses three proprietary AI platforms to design drug delivery systems. Its revenue surged to 105 million yuan in 2025 from 1.48 million yuan in 2024, while net loss narrowed to 391.8 million yuan. Its leading drug candidate MTS-004 for pseudobulbar affect has completed phase three trials.
